Skip to main content

Table 1 Clinical features and concomitant treatment of the cohort

From: B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus

 SLE patients (n = 18)
Baseline SLEDAI, median (IQR)6 (4)
Follow-up SLEDAI, median (IQR)5 (2)*
Indication for starting belimumab
 Musculoskeletal involvement, n (%)12 (66.7)
 Mucocutaneous involvement, n (%)5 (27.8)
 Lung involvement, n (%)1 (5.5)
Concomitant treatment
 Glucocorticoids, n (%)18 (100)
 Hydroxychloroquine, n (%)17 (94.4)
 Mycophenolate, n (%)5 (27.8)
 Azathioprine, n (%)4 (22.2)
 Cyclosporine, n (%)3 (16.7)
 Methotrexate, n (%)2 (11.1)
 Thalidomide, n (%)1 (5.5)
  1. *p = 0.001 vs baseline